Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00160667
Status:
COMPLETED
Last Update Posted:
2019-01-31
First Post:
2005-09-08
Brief Title:
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles Post-herpetic Neuralgia
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
An Exploratory Double Blind Randomized Placebo-controlled Parallel Group Multicenter Study for the Assessment of Efficacy Safety and Tolerability of Ucb 34714 50 mg Oral Capsules in bid Administration at the Doses of 200 mgDay and 400 mgDay in Subjects at Least 18 Years Old Suffering From Post Herpetic Neuralgia PHN
Status:
COMPLETED
Status Verified Date:
2018-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Study will assess efficacy safety and tolerability of brivaracetam in post-herpetic neuralgia PHN Duration of 7 weeks divided into 3 periods with no up-titration nor down-titration
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2004-000975-32 | EUDRACT_NUMBER | None | None |